MDXXF (Pharmala Biotech Holdings) Gross-Profit-to-Asset % : 16.48% (As of Feb. 2025)

View and export this data going back to 2023. Start your Free Trial

What is Pharmala Biotech Holdings Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Pharmala Biotech Holdings's annualized Gross Profit for the quarter that ended in Feb. 2025 was $0.38 Mil. Pharmala Biotech Holdings's average Total Assets over the quarter that ended in Feb. 2025 was $2.31 Mil. Therefore, Pharmala Biotech Holdings's annualized Gross-Profit-to-Asset % for the quarter that ended in Feb. 2025 was 16.48%.

Pharmala Biotech Holdings Gross-Profit-to-Asset % Historical Data

The historical data trend for Pharmala Biotech Holdings's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmala Biotech Holdings Gross-Profit-to-Asset % Chart

Pharmala Biotech Holdings Annual Data

Trend

Aug21

Aug22

Aug23

Aug24

Gross-Profit-to-Asset %

2.93

18.75

33.23

Pharmala Biotech Holdings Quarterly Data
	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	Aug24	Nov24	Feb25
Gross-Profit-to-Asset %	Get a 7-Day Free Trial										76.13	9.16	-	8.19	16.48

Competitive Comparison of Pharmala Biotech Holdings's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Pharmala Biotech Holdings's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmala Biotech Holdings's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmala Biotech Holdings's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Pharmala Biotech Holdings's Gross-Profit-to-Asset % falls into.

Save Embed

;

Save Embed

;

Pharmala Biotech Holdings Gross-Profit-to-Asset % Calculation

Pharmala Biotech Holdings's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Aug. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Aug. 2024 )	/	( (Total Assets (A: Aug. 2023 )	+	Total Assets (A: Aug. 2024 ))	/ count )
	=	0.65	/	( (1.79	+	2.122)	/ 2 )
	=	0.65	/	1.956
	=	33.23 %

Pharmala Biotech Holdings's annualized Gross-Profit-to-Asset % for the quarter that ended in Feb. 2025 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Feb. 2025 )	/	( (Total Assets (Q: Nov. 2024 )	+	Total Assets (Q: Feb. 2025 ))	/ count )
	=	0.38	/	( (1.881	+	2.732)	/ 2 )
	=	0.38	/	2.3065
	=	16.48 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Feb. 2025) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Pharmala Biotech Holdings Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Pharmala Biotech Holdings's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmala Biotech Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (OTCPK:MDXXF) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

MDMA:Canada

Address

1 Adelaide Street East, Suite 801, Toranto, ON, CAN, M5C 2V9

Website

https://www.pharmala.ca

Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. Its drug API is manufactured and encapsulated under GMP conditions. The company generates revenue from the sale of tablets and raw MDMA and MDXX compounds/formulations and royalties from licensing of its IP.